Pfizer again supplying pain drugs to veterinarians shunted aside because of hospital shortages

Dog and cat
Vets are again getting limited supplies of injected pain drugs they need to use on animals for surgeries or pain from trauma. (Pixabay)

Pfizer shut off supplies of pain drugs to veterinarians when a shortage of an injected opioid meant it couldn’t fill all of the orders it had from hospitals. But relief is now on the way for vets and their animal patients, the FDA says.

The FDA’s Center for Veterinary Medicine (CVM) says it has reached an agreement for Pfizer to divert part of a new source of the drugs for use by veterinarians.

“As a result of CVM’s recent discussion with Pfizer, this product is now available in limited quantities for pain management in animals,” the agency said. “ … Injectable opioids are used in animals to treat pain following severe trauma and to control pain during and after surgery. Adequate pain control is essential in animals, as in humans.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The drugs will come from a supply the FDA earlier allowed (PDF) Pfizer to import from Canada. Because of the nationwide shortage, the FDA permitted the drug company to buy hydromorphone hydrochloride injection, USP, in 2 mg/ml strength, 1 ml volume ampules from Sandoz, which makes them at a plant in Canada for the Canadian market. Although the labeling is different from the same drug sold in the U.S., it is otherwise identical.

RELATED: Pfizer halts sales of injectable opioids to veterinarians as shortages persist  

In addition to making some of this supply available to the vet market, Pfizer has also agreed to make morphine sulfate injection, USP available to the U.S. veterinary market when supply increases.

Pfizer last summer suspended sales of injected pain drugs to the veterinary market, diverting those drugs to fill orders from hospitals. It said it would be unable to resume sales for animal use until the shortage at hospitals and surgical facilities has been resolved, which it did not expect to happen before the second quarter of 2019.

The shortage of the hospital-administered pain medications, including morphine and fentanyl, started in 2017 when Pfizer reduced output of prefilled syringes as part of an upgrade at its troubled Hospira sterile drug manufacturing site in McPherson, Kansas.

RELATED: Pfizer still unable to get on top of problems at Hospira injectables plant 

Last year, Pfizer told customers that because upgrades were taking longer than expected, "full recovery dates of prioritized prefilled syringes” had moved to the first quarter of 2019 and deprioritized syringes to the second quarter of 2019.  

While production has resumed, the FDA continues to find issues with the plant. An inspection in July and August resulted in eight observations, seven of them repeats. In response, Pfizer said the site developed and implemented a “robust corrective and preventive action plan” after the inspection. “While there is still additional work to be done against our plan, the site has made significant improvements and progress since the inspection.”

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.